Copying and distributing are prohibited without permission of the publisher.

Watermark

Simcere Pharma nets $461m from top-end pricing

biopharma_stocks_adobe_575x375.jpg
By Jonathan Breen
20 Oct 2020

Simcere Pharmaceutical Group has bagged HK$3.57bn ($460.6m) from its IPO, after sealing the offer at the top end of the price guidance, according to a source familiar with the deal.

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free Trial
By Jonathan Breen
20 Oct 2020